PDCD1 and non-small cell lung carcinoma: Taken together with these results, the combination of peripheral T cell cytotoxicity and the peripheral CD45RA+CD25+/CD4+ T cell ratio predicted the efficacy and severe adverse events of anti-PD-1 therapy for advanced NSCLC patients.